Scientists have deciphered how deficiency of the enzyme GCase—a strong risk factor for #ParkinsonsDisease—provokes neuron-damaging inflammation in the brain, and show that targeting the STING immune pathway can counteract these effects. @SciSignal scim.ag/6Au

We're extending our Phase 2b ASPIRE Clinical Study evaluating #UBX1325 in DME from 24 weeks to 36 weeks, allowing us to assess potentially greater durability compared to standard of care. Learn more about our next steps: bit.ly/3xP09jw $UBX

The energy revolution is here!

Cool science that will require #visionary long-term #investors to create a world where #aging is a choice How to kill the ‘zombie’ cells that make you age nature.com/articles/d4158…

Recently, CEO Anirvan Ghosh, Ph.D. spoke with Carissa Wong at @nature to discuss #senescence, current research in #senolytics, and our senolytic candidate #UBX1325’s recent clinical data and upcoming milestones. Learn about our novel approach: bit.ly/3QPwlcZ

Our senolytic candidate #UBX1325 is designed to selectively eliminate senescent cells, potentially restoring aging or damaged tissues to a more functionally healthy state. Learn more about our senolytic approach to treating #DME: bit.ly/47jqyD3  #HealthyVisionMonth

Senescent glia link mitochondrial dysfunction and lipid accumulation | Nature nature.com/articles/s4158…

Our Chief Scientist Mike Sapieha, Ph.D. joined the Drug Discovery News DDN Dialogues podcast with host Stephanie DeMarco, PhD to break down our senolytic model and #UBX1325’s recent clinical trial success in improving vision and eye health in patients with #DME. bit.ly/3VBfCf7

Excited to welcome Alicia Tozier to UNITY as Chief Strategy Officer! #unitybiotechnology #DME

Mike McFaul’s take on Harris and Ukraine. U.S. must fully remain engaged with NATO and stand with Ukraine in this conflict open.substack.com/pub/michaelmcf…

Today is National Voter Registration Day! Take a few minutes to visit IWillVote.com/Obama and make sure you’re registered and have a plan to vote. Then check in with your friends and family and make sure they’re registered, too. Let’s get it done.

Register and vote! Go to Iwillvote.com 🇺🇸🇺🇸🇺🇸

Congrats to Svetlana Mojsov, Joel Habener, and Lotte Knudsen on being recognized for their groundbreaking work on the identification of GLP1 agonists, the foundation of today’s anti-obesity drugs! nytimes.com/2024/09/19/hea… via @NYTimes

Save the date! Join us at our Ophthalmology Day for Investors and Analysts on Oct. 15, where we'll feature presentations from retinal experts & members of the UNITY management team focused on the Phase 2b ASPIRE study of #UBX1325 in DME. More: bit.ly/3ZEz66f $UBX

If you have a mail-in ballot, do one thing this weekend. VOTE EARLY! Be heard, not only for President but also for down ballot candidates - let’s get some good people in office 🇺🇸🇺🇸🇺🇸 YOUR VOTE MATTERS

We’re buzzing with energy from #JPM25 — it’s always a pleasure to connect with investors and potential partners in #biotech. We're looking forward to sharing topline results from the Ph2B ASPIRE study in Q1 as we continue efforts to bring forward new treatment options for #DME.

The growing #DME population faces significant challenges, with many experiencing suboptimal treatment response and vision decline. #UBX1325 aims to address this unmet need and improve long-term outcomes. Learn more below and stay tuned for Phase 2b ASPIRE study results.

The Phase 2 BEHOLD study data results of UBX1325 in patients with diabetic macular edema (DME) were published in the NEJM Evidence peer-reviewed journal. Read the full announcement and access the article: ir.unitybiotechnology.com/news-releases/…

Excited to announce the launch of my podcast ‘Let’s Talk About That’ where we discuss the ideas, people, and events shaping our world. In this episode I sit down with exec coach and thought leader Joanna Kirke, MBA to discuss her journey open.spotify.com/episode/5YTahn…

Meet Joanna Kirke, MBA our lead-off guest in the brand new podcast, Let’s Talk About That open.spotify.com/watch-feed/art…